Free Trial

Korro Bio (KRRO) Competitors

Korro Bio logo
$12.90 -0.19 (-1.45%)
As of 03:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

KRRO vs. ATYR, KMDA, ATAI, TRML, MREO, RGNX, PGEN, RAPP, ORKA, and PRTC

Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include aTyr Pharma (ATYR), Kamada (KMDA), atai Life Sciences (ATAI), Tourmaline Bio (TRML), Mereo BioPharma Group (MREO), REGENXBIO (RGNX), Precigen (PGEN), Rapport Therapeutics (RAPP), Oruka Therapeutics (ORKA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry.

Korro Bio vs. Its Competitors

Korro Bio (NASDAQ:KRRO) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

In the previous week, aTyr Pharma had 1 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for aTyr Pharma and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.83 beat aTyr Pharma's score of 0.66 indicating that Korro Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Korro Bio
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
aTyr Pharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Korro Bio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

aTyr Pharma has lower revenue, but higher earnings than Korro Bio. aTyr Pharma is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$2.27M53.36-$83.58M-$9.44-1.37
aTyr Pharma$230K2,033.07-$64.02M-$0.81-6.49

Korro Bio currently has a consensus target price of $102.43, indicating a potential upside of 694.02%. aTyr Pharma has a consensus target price of $20.20, indicating a potential upside of 284.47%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts plainly believe Korro Bio is more favorable than aTyr Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
aTyr Pharma
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14

Korro Bio's return on equity of -51.64% beat aTyr Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro BioN/A -51.64% -37.94%
aTyr Pharma N/A -87.09%-64.77%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 3.7% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Korro Bio beats aTyr Pharma on 10 of the 16 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRRO vs. The Competition

MetricKorro BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$121.13M$2.41B$5.48B$9.01B
Dividend YieldN/A1.77%5.39%4.10%
P/E Ratio-1.378.9827.4320.06
Price / Sales53.36468.84398.47108.02
Price / CashN/A151.5836.1356.90
Price / Book0.754.638.085.67
Net Income-$83.58M$31.34M$3.16B$248.47M
7 Day Performance4.54%0.84%2.12%2.90%
1 Month Performance8.13%7.92%4.43%5.75%
1 Year Performance-66.34%1.87%35.62%21.36%

Korro Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRRO
Korro Bio
2.5572 of 5 stars
$12.90
-1.5%
$102.43
+694.0%
-60.5%$121.13M$2.27M-1.3770
ATYR
aTyr Pharma
2.9858 of 5 stars
$5.07
+0.8%
$20.20
+298.4%
N/A$447.69M$230K-6.2653Gap Up
High Trading Volume
KMDA
Kamada
4.1674 of 5 stars
$7.75
+0.5%
$14.67
+89.2%
+54.8%$443.36M$160.95M26.72360Positive News
ATAI
atai Life Sciences
3.1394 of 5 stars
$2.19
-0.5%
$8.67
+295.7%
+111.5%$440.74M$310K-2.4180News Coverage
Analyst Forecast
Options Volume
TRML
Tourmaline Bio
2.1447 of 5 stars
$15.99
-3.3%
$49.33
+208.5%
+29.0%$424.84MN/A-4.9844
MREO
Mereo BioPharma Group
1.9449 of 5 stars
$2.71
+1.9%
$7.60
+180.4%
-16.8%$422.94M$10M-38.7140
RGNX
REGENXBIO
4.415 of 5 stars
$8.21
-2.1%
$31.63
+285.2%
-19.8%$420.85M$83.33M-2.64370
PGEN
Precigen
3.7317 of 5 stars
$1.42
flat
$6.00
+322.5%
+8.1%$419.16M$3.92M-2.54190News Coverage
RAPP
Rapport Therapeutics
1.9466 of 5 stars
$11.37
-0.5%
$32.67
+187.3%
-52.8%$417.17MN/A-3.30N/ANews Coverage
Gap Up
ORKA
Oruka Therapeutics
2.219 of 5 stars
$11.21
+1.2%
$40.38
+260.2%
N/A$414.84MN/A-2.49N/A
PRTC
PureTech Health
2.6077 of 5 stars
$17.25
+0.6%
$45.00
+160.9%
-27.6%$411.92M$4.83M0.00100Gap Up

Related Companies and Tools


This page (NASDAQ:KRRO) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners